Morgan Stanley Raises PT on Ultragenyx Pharmaceutical (RARE) by 92% on High Potential of Angelman Drug
Tweet Send to a Friend
Morgan Stanley analyst Jeffrey Hung nearly doubled his price target on Ultragenyx Pharmaceutical (NASDAQ: RARE) to $175.00 per share from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
